trial
as of 2026-07-01A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
NCTId NCT01566162
at a glance
Phase 3 · Completed
Enrollment 191 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2013-11
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
191 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2012-04
Primary completion
2013-11
Eligibility
ALL · 18 Years
Interventions & indications
Drugs
Indications
Sponsors
Sumitomo Pharmaceuticals AmericaLead Sponsor
Investigators
1
Lurasidone Medical Director, MDStudy Director
Sites
63 total
Little Rock, United StatesLittle Rock, United StatesCerritos, United StatesDowney, United StatesEscondido, United StatesGarden Grove, United StatesLos Angeles, United StatesNational City, United StatesOceanside, United StatesPico Rivera, United StatesSan Diego, United StatesSanta Ana, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
191
Phase
PHASE3
Primary Completion Date
2013-11
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
indication
indication
investigator